Proton (1H) magnetic resonance spectroscopy, brain neurochemistry, and diagnosis of neurological diseases;Espectroscopia de prótons (1H) por ressonância magnética, neuroquímica cerebral e diagnóstico de doenças neurológicas

Revista Brasileira de Neurologia

Volumn 36, Issue 1, 2000, Pages 11-25

  Engelhardt, Eliasz ^a   Moreira, Denise Madeira ^a   Laks, Jerson ^a   Rozenthal, Marcia ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Magnetic resonance; Neurochemistry; Neurological diseases; Proton spectroscopy

Indexed keywords

EID: 0039369272     PISSN: 01018469     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Agranoff BW, Benjamins JA e Hajra AK. Lipids. In: Basic Neurochemistry; Molecular, Cellular and Medical Aspects, 6th ed, ed Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD. Philadelphia: Lippincott-Raven; p. 47-67, 1999.
2. Albers RW. Cell Membrane Structures and Functions. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th ed, ed Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD. Philadelphia: Lippincott-Raven: p. 31-46, 1999.
3. Bear MF, Connors BW e Paradiso MA. Neuroscience: Exploring the Brain., Baltimore: Williams & Wilkins; 1996.
4. Block W, Traber f, Kuhl CK, Fric M, Keller E, Lamerichs R, Rink H, Möller HJ e Schild HH - 1H-MR-spektroscopische Bildgebung bei Patienten mit klinisch gesichertem Morbus Alzheimer. Röntgenstr: Fortschr 1995;163:230-7.
5. Blusztajn JK, Gonzalez-Coviella IL, Logue M, Growdon JH e Wurtman RJ. Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerphosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients. Brain Res 1990;536:240-4..
6. Butterworth RF. Metabolic Encephalopathies. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK, MD, eds. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 769-82, 1999.
7. Castillo M, Kwock L. Proton MR Spectroscopy of Common Brain Tumors.- Neuroimaging Clin N Am 1998; 8:733-52.
8. Cendes R, Andermann F, Preul MC, Arnold DL. Lateralization of Temporal Lobe Epilepsy Based on Regional Metabolic Abnormalities in Proton Magnetic Resonance Spectroscopic Images. Ann Neural 1994; 35:211-6.
9. Chang L, Ernst T, Poland RE, Jenden DJ. In Vivo Proton Magnetic Resonance Spectroscopy of the Normal Aging Human Brain.- Life Sci 1996; 58:2049-56.
10. Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Patterson LJ, Doraiswamy PM, McDonald WM. Proton Spectroscopy of Human Brain: Effects of Age and Sex.- Prog Neuropsychopharmacol Biol Psychiatry 1994;18:995-1004.
11. Cheng LL, Ma MJ, Becerra L. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance Spectroscopy. Proc Natl Acad Sci USA 1998;94:6408-13.
12. Clarke D, Sokoloff L. Circulation and energy Metabolism of the Brain. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK, and MD, eds. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 637-69, 1999.
13. Choi CG, Frahm J. Localized Proton MRS of the Human Hippocampus: Metabolite Concentrations and Relaxation Times. Magn Reson Med 1999; 41:204-7.
14. Confort-Gouny S, Vion-Dury J. Nicoli F. Dano P, Donnet A. Grazziani N, Gastaut JL, Grisoli F, Cozzone PJ. A multiparametric data analysis showing the potential of localized proton MR spectroscopy of the brain in the metabolic characterization of neurological disease. J Neural Sci 1993; 118:123-33.
15. Corrigan FM, Horrobin DF, Skinner ER, Besson JAO, Cooper MB. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglicerydes and cholesterol esters of parahipocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem & Cell Biol 1998;30:197-207.
16. Danielsen ER, Ross B. Magnetic Resonance Spectroscopy Diagnosis of Neurologiacal Diseases. New York: Marcel Dekker; 1999.
17. Davie CA, Wenning GK, Barker GJ. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-10.
18. Dingledine R, McBain CJ. Glutamate and Aspartate. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th ed. ed Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD. Philadelphia: Lippincott-Raven; p. 315-34, 1999.
19. Dugan LL, Choi DW, Hypoxic-Ischemic Brain Injury and Oxidative Stress. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th ed, ed Sigel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Philadelphia: Lippincott-Raven; p.711-30, 1999.
20. Doraiswamy PM, Charles HC, Krishnan KRR. Prediction of cognitive decline in early Alzheimer's disease. Lancet, 1998; 352(21): 1678.
21. Duncan JS. Magnetic Resonance Spectroscopy. Epilepsia 1996;37:598-605.
22. Engelhardt E, Rozenthal M, Marinho V, Souza F, Moreira D, Lachetermacher R, Laks J, Villela Pedras P. Diagnostic Markers for Alzheimer's Disease. Abstracts 1999a;.II:136.
23. Engelhardt E, Moreira DM, Laks J, Marinho VM, Rozenthal M, Cavalcanti JLS, Oliveira AC. Espectroscopia por Ressonância Magnética do Hipocampo: Normatização no Idoso - Resultados Preliminares/Magnetic Resonance Spectroscopy of the Hippocampus: Normalization in the Elederly - Preliminary Results. II Reunião de Pesquisadores em Doença de Alzheimer e Desordens Relacionadas. Resumos/Abstracts. Arq Neuropsiquiatr 1999b; 57(Suppl 1):11-12, 43.
24. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal Dementia and Early Alzheimer Disease: Differentiation with Frontal Lobe H-I MR Spectroscopy. Radiologyn. 1997; 203:829-36.
25. Federico F, Simone IL, Lucivero V, Iliceto G, De Mari M, Giannini P, Mezzapesa DM, Tarantino A e Lamberti P. Proton Magnetic Resonance Spectroscopy in Parkinson's Disease and Atypical Parkinsonian Disorders. Mov Disord 1997;(12):903-9.
26. Fisher SK e Agranoff BW - Phosphoinositides. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 415-32, 1999.
27. Fisher SK, Heacock AM, Agranoff BW. Inositol Lipids and Signal Transduction in the Nervous System: An Update. J Neurochem 1992; 58:18-38.
28. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized proton NMR Spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Mag Res Med 1989;11:47-63.
29. Frahm J, Hanefeld F. Localized Proton Magnetic Resonance Spectroscopy of Cerebral Metabolites,- Neuropediatrics 1996; 27:64-9.
30. Frahm J, Bruhn H, Gyngell ML. Localized Proton MR Spectroscopy. A Non-Invasive Insight into Brain Metabolism.. Radiologe 1991;31:558-66.
31. Frahm J, Hanefeld F. Localized Proton Magnetic Resonance Spectroscopy of Cerebral Metabolites.- Neuropediatrics 1996; 27:64-69.
32. Fuchs A . GE Medical Systems on Line Center, 1999.
33. Furuya H, Sugimura Y, Yamada T, Hayashi K, Kobayashi T. A case of incomplete Kearns Sayre syndrome with a stroke like episode. Rinsho Shinkeigaku 1997;(37):680-4.
34. González RG, Plak T. Magnetic Resonance of Degenerative Brain disease in the Elderly In: Clinical Applications of Magnetic Resonance Spectroscopy. New York: SK Mukherji, Wiley-Liss; p. 143-61, 1998
35. Haseler LJ, Sibbit WL, Mojtahedzadeh HN, Reddy S, Agarwal VP, McCarthy DM. Proton MR Spectroscopic Measurement of Neurometabolites in Hepatic Encephalopathy during Oral Lactulose Therapy. Am J Neuroradiol 1998,19:1681-6.
36. Hurley RA, Jackson EF, Fisher RE, Taber KH. New Techniques for Understanding Huntington's Disease. J Neurpsychaitry Clin Neurosci 1999;11:173-5.
37. Heun R, Schlegel S, Graf-Morgenstern M. Proton Magnetic Resonance Spectroscopy in Dementia of Alzheimer Type. Int J Genat Psychiatry 1997;12:349-58.
38. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Morris RG, dough C, Brooks DJ, Turjanski N - Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR Spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67:20-26.
39. Jope RS; Jenden DJ. Choline and Phospholipid Metabolism and the Synthesis of Acetylcholine in Rat Brain.. J Neurosci Res 1979 4:69-82.
40. Klunk WE, Panchalingam K, Moossy J, McClure RJ e Pettegrew JW - N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: A preliminary proton nuclear magnetic resonance study. Neurology 1992 42:1578-85.
41. Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative 1H and 3IP MRS of PCA Extracts of Postmortem Alzheimer's Disease Brain. Neurobiol Aging 1996; 17:349-57.
42. Kohler S. Signa Advantage Applications Guide. Vol V. Single-Voxel Proton Brain Exam Applications Guide. 1st ed. General Eletric Company, 1994.
43. Kwock L. Clinical Proton Magnetic Resonance Spectroscopy: Basic Principlesm In: Clinical Applications of Magnetic Resonance Spectroscopy. New York: SK Mukherji, Wiley-Liss; p. 1-31, 1998.
44. Landtblom AM, Sjoqvist L, Soderfeldt B, Nyland H, KA. Proton MR Spectroscopy and MR imaging in acute and chronic multiple sclerosis - ringlike appearances in acute plaques. Acta Radiol 1996;37(3 Pt 1):278-87.
45. Laubenberger J, Haussinger D, Bayer S, Thielemann S, Schneider B, Mundinger A, Hennig J, Langer M - HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996;199:805-10.
46. Laubenberger J, Bayer S, Thiel T, Hennig J, Langer M. Clinical uses of proton magnetic resonance Spectroscopy of the brain. Fortschr. Röntgenstr 1998; 168:539-49.
47. Lazeyras F, Charles HC, Tuples LA. Erickson R, Boyko OB, Krishnan KRR . Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psychiatry Res: Neuroim Sec 1998; 82:95-106.
48. Loffeiholtz K. Brain Choline Has a Typical Precursor Profile. J Physiol Paris l998;92:235-9.
49. Magistretti PJ, Pellerin L, Rothman DL, Shuiman RG. Energy on Demand.- Science 1999;283:496-7,.
50. Manton DJ, Lowry M, Blackband SJ, Horsman A. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumors. NMR Biomed 1995; 8:104-12.
51. Mathews VP, Barker PB, Blackband SJ, Chatham JC, Bryan RN. Cerebral metabolites in patients with acute and subacute strokes: concentrations determined by quantitative proton MR spectroscopy. Am J Roentgenol 1995;165:633-8.
52. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Dyke C, Fein G e Weiner MW. Axonal Injury and Membrane Alterations in Alzheimer's Disease Suggested by In Vivo Proton Magnetic Resonance Spectroscopic Imaging. Ann Neurol 1994;36:40-7.
53. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated Subcortical Choline Metabolites in Cognitively and Clinically Asymptomatic HIV+ Patients. Neurology 1999; 53:995-1003.
54. Meyerand ME, Pipas JM. Mamourian A. Tosteson TD, Dann JF. Classification of Biopsy Confirmed Brain Tumors Using Single Voxel MR Spectroscopy. Am J Neuroradiol 1999;20:117-23.
55. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47-52.
56. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer Disease: Depiction of Increase Cerebral Myo-Inositol with Proton MR Spectroscopy. Radiology 1993;187:433-7.
57. Moats RA, Shonk T. Evaluation of Automated MR Spectroscopy: Application in Alzheimer disease.- Am J Neuroradiol 1995;16:1779-82.
58. Moffett JR, Namboodiri MA e Neale JH. Enhanced Carbodiimide Fixation for Immunohistochemistry: Application to the Comparative Distributions of N-Acetylaspartylglutamate and N-acetylaspartate Immunoreactivities in Rat Brain.. J Histochem Citochem 1993;41):559-70.
59. Moreira DM, Giorelli AS, Gomes MM. Espectroscopia por ressonância magnética em epilepsia. Rev bras Neurol 1999;35:105-9.
60. Morell P, Quarles RH. Myelin Formation, Structure and Biochemistry. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 69-93, 1999.
61. Olsen RW, DeLorey TM. GABA and Glycine. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p.335-46, 1999.
62. Parnetti L, Lowenthal DT, Presciutti O, Pelliccioli G, Palumbo R, Gobbi G, Chairini P, Palumbo B, Tarducci R, Senin U. 1H-MRS-Based Hippocampal Volumetry, and 99mTc-HMPAO-SPECT in Normal Aging, Age-Associated Memory Impairment, and Probable Alzheimer's Disease. JAGS 1996; 44:133-8.
63. Pavlakis SG, Kinsley PB, Kaplan GP, Stacpoole PW, O'Shea M, Lustbader D. Magnetic resonance spectrscopy: use in monitoring MELAS treatment. Arch Neurol 1998; 55:849-52.
64. Peitegrew JW, Klunk WE, Pachalingam K, McClure RJ e Stanley JA. Magnetic Resonance Spectroscopic Changes in Alzheimer's Disease. Ann NY Acad Sci 1997;826:282-306.
65. Peters A, Palay S e Webster HF. The Fine Structure of the Nervous System Philadelphia: Saunders; 1976.
66. Peters AR, Geelen JA, den Boer JA, Prevo RL, Minderhound JM, 's Grravenmade EJ. A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging. Mult Scler 1995;1:25-31.
67. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial Observations on the Effect of Vigabatrin on In Vivo 1H Spectroscopic Measurments of g-Aminobutiric Acid, Glutamate and Glutamine in Human Brain.. Epilepsia 1995;36:457-64.
68. Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ, Stanley JA. Magnetic Resonance Spectroscopic Changes in Alzheimer's Disease. Ann NY Acad Sci 1997;826:282-306.
69. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In Vivo Spectroscopic Quantification of the N-acetyl moiety, Creatine and Choline from Large Volumes of Brain Gray and White Matter Effects of Normal Aging. Magn Reson Med 1999 41:276-84.
70. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In Vivo Brain Concentrations of N-Acetyl Compounds, Creatine, and Choline in Alzheimer's Disease. Arch Gen Psychiatry 1999; 56:185-92.
71. Pouwels PJ, Frahm J. Differential Distribution of NAA and NAAG in Human Brain as Determined by Quantitative Localized Proton MRS. NMR Biomed 1997;10:73-8.
72. Pouwels PJ, Frahm J. Regional Metabolite Concentrations in Human Brain as Determined by Quantitative Localized Proton MRS. Magn Res Med 1998;39:53-60.
73. Raine CS. Neurocellular Anatomy. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 3-30, 1999.
74. Rhinehart DL, Cox LA, Long BW . MR Spectroscopy of Alzheimer Disease. Radiol Technol 1998;70:23-8.
75. Ricci PE. Proton MR Spectroscopy in Ischemic Stroke and Other Vascular Disorders. Neuroimaging Clin N Am 1998;8:881-900.
76. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Crueller R. In vivo magnetic resonance Spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem 1997;68:161-72.
77. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In Vivo MR Spectroscopy of Human Dementia.- Neuroimaging Clin N Am 1998; 8:809-22.
78. Rudkin TM, Arnold DL. Proton Magnetic Resonance Spectroscopy for the Diagnosis and Management of Cerebral Disorders-Arch Neurol 1999; 56:919-26.
79. Salvan A, Vion-Dury J, Confort-Gouny S, Sangla I, Pouget J, Cozzone PJ. Brain metabolic profiles obtained by proton MRS i two forms of mitocondriopathies: Leber's hereditary optic neuropathy and chronic progressive external ophtalmoplegia. Eur Neurol 1998;40:46-9.
80. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced Cortical gama-Aminobuiyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance spectroscopy.. Arch Gen Psychiatry 1999;56:1043-7.
81. Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, Alberti A, Vicinanza F, Gallai V. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999;122:513-21.
82. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain Proton Magnetic Resonance Spectroscopy (1H-MRS) in alzheimer's Disease: Changes After treatment With Xanomeline, an M1 Selective Cholinergic Agonist.- Am J Psychiatry 1997;154:1459-61.
83. Saunders DE, Howe FA, Boogaart A, Griffiths JR, Brown MM. Aging of the Adult Human Brain: In Vivo Quantitation of Metabolite Content with Proton Magnetic Resonance Spectroscopy. J Magn Reson Imaging 1999;9:711-6.
84. Schuff N, Amend D, Ezekiel BA, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH. Mastrianni JA, Fein G, Weiner MW. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: A proton MR spectroscopic imaging and MRI study. Neurology 1997:49:1513-21.
85. Schuff N, Amend D, Meyerhoff DJ, Tanabe J, Norman D, Fein G, Weiner MW. Alzheimer's Disease: Quantitative H-1 MR Spectroscopic Imaging of Frontoparietal Brain. Radiology 1998; 207:91-102.
86. Schwartz JH. Synthesis and Trafficking of Neuronal Proteins. In: Kandel ER, Schwartz JH e Jessel TM, editors. Principles Of Neural Science. 3rd ed. New York: Elsevier; p. 49-65, 1991.
87. Schwartz JH, Kandel ER. Synaptic Transmission Mediated By Second Messengers. In: Kandet ER, Schwartz JH e Jessel TM, editors. Principles Of Neural Science. 3rd ed. New York: Elsevier; p. 173-93,1991.
88. Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. Proton Magnetic Resonance Spectroscopy with Dementia. Surg Neurol 1993;39:143-7.
89. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD . Probable Alzheimer Disease: diagnosis with Proton MR Spectroscopy. Radiology 1995;195:65-72.
90. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical Localization of N-Acetyl-Aspartate with Monoclonal Antibodies. Neuroscience 1991;45:37-45.
91. Suojanen JN, Barker BP. Magnetic Resonance Spectroscopy and Spectroscopic Imaging for Cerebrovascular disease. In: Clinical Applications of Magnetic Resonance Spectroscopy. New York: Wiley-Liss; p. 105-42, 1998.
92. Taylor-Robinson SD, Weeks RA, Bryant DJ. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favor of glutamate excititoxic theory. Mov Dosord 1996;11:67-73.
93. Tedeschi G, Bertolino A, Reghini A, Campbell G, Raman R, Duyn JH, Moonen CTW, Alger JR, Di Chiro G. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 1995;45:1384-91.
94. Tedeschi G, Bertolino A, Lundbon N, Bonavita S, Patronas NJ, Duyn JH, Metman LV, Chase TN, Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopi imaging. Neurology 1996;47:696-704.
95. Thompson JE, Castillo M, Kwock L. Magnetic Resonance Spectroscopy in the evaluation of Epilepsy. In: Clinical Applications of Magnetic Resonance Spectroscopy. Nev York: Wiley-Liss; p. 33-47,1998.
96. Urenjak J, Williams SR, Gadian DG, Noble M. Specific Expression of N-Acetylaspartate in Neurons, Oligodendrocyte-Type-2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro. J Neurochem 1992;59:55-61.
97. Urenjak J, Williams SR, Gadian DG, Noble M. Proton Nuclear Magnetic Resonance Spectroscopy Unambiguously Identifies Different Neural Cell Types. J Neurosci 1993; 13:981-9.
98. Usenius JR Kauppinen RA, Vainio PA, Hernesniemi JA, Vapalahti MP Paljarvi LA, Soimakallio S. Quantitative metabolite patterns of human brain tumors: detection by 1H NMR spectroscopy in vivo and in vitro. J Comput Assist Tomogr 1994;18::705-13.
99. Voet D, Voet JG. Biochemistry. 2nd ed. New York: John Wiley & Sons; 1995.
100. Walker NP. Fox HC, Whalley LJ. Lipids and Schizophrenia. Br J Psychiatry 1999; 174:101-4.
101. Wang Y, Li SJ. Differentiation of Metabolic Concentrations Between Gray Matter and White Matter of Human Brain by In Vivo 1H Magnetic Resonance Spectroscopy. Magn Reson Med 1998;39:28-33.
102. Wang AJ. Zimmerman RA. Proton MR Spectroscopy of Pediatric Brain Metabolic Disorders. Neuroimaging Clin N Am 1998;8:781-807.
103. Yudkoff M. Disease of Amino Acid Metabolism. In: Sigel GJ, Agranoff BW, Albers RW, Fisher SK e Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; p. 887-915, 1999.